Literature DB >> 12020175

Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction.

James E Dalen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12020175     DOI: 10.1001/archinte.162.10.1091

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


× No keyword cloud information.
  6 in total

Review 1.  Selective COX-2 inhibitors: a health economic perspective.

Authors:  David L B Schwappach; Christian M Koeck
Journal:  Wien Med Wochenschr       Date:  2003

2.  Do selective cyclo-oxygenase-2 nonsteroidal anti-inflammatory agents increase the risk for acute myocardial infarction?

Authors:  Joseph S Alpert
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

3.  Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans.

Authors:  C J Hawkey; J I Jones; C T Atherton; M M Skelly; J R Bebb; U Fagerholm; B Jonzon; P Karlsson; I T Bjarnason
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

Review 4.  Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.

Authors:  C J Hawkey; M J S Langman
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

5.  COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.

Authors:  Marc C Hochberg
Journal:  Arthritis Res Ther       Date:  2002-12-11       Impact factor: 5.156

6.  Acute coronary disease Athero-Inflammation: Therapeutic approach.

Authors:  Raul Altman
Journal:  Thromb J       Date:  2003-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.